Cargando…
Fulminant Myocarditis With ST Elevation and Cardiogenic Shock in a SARS-CoV-2 Patient
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first described in patients in Wuhan, China, who presented with flu-like symptoms. Since then, it has spread all over the world and in March 2020 it was labeled as a pandemic by the World Health Organization. Most common presentations...
Autores principales: | Ghafoor, Khuzema, Ahmed, Aftab, Abbas, Mubasher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260201/ https://www.ncbi.nlm.nih.gov/pubmed/34262828 http://dx.doi.org/10.7759/cureus.16149 |
Ejemplares similares
-
Fulminant myocarditis and cardiogenic shock during SARS-CoV-2 infection()
por: Lozano Gómez, Herminia, et al.
Publicado: (2020) -
COVID-Induced Fulminant Myocarditis
por: Rodriguez Guerra, Miguel A, et al.
Publicado: (2022) -
Target Vessel Versus Complete Revascularization in Non-ST Elevation Myocardial Infarction Without Cardiogenic Shock
por: Pandit, Neeraj, et al.
Publicado: (2022) -
Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock
por: Itzhaki Ben Zadok, Osnat, et al.
Publicado: (2019) -
Cardiogenic Shock in COVID 19 Fulminant Myocarditis Treated with V-A ECMO
por: D'Errico Ramirez, A., et al.
Publicado: (2022)